MarketPulse

CNS diseases

3 articles
BenzingaBenzinga··Globe Newswire

Reviva Pharmaceuticals Closes $10M Offering to Fund Schizophrenia Drug Trial

Reviva Pharmaceuticals closed a $10M public offering at $1.50/share to fund its RECOVER-2 Phase 3 schizophrenia trial, maintaining $23M cash through Q1 2027.
RVPHwarrantspublic offering
BenzingaBenzinga··Globe Newswire

Reviva Pharma Raises $10M via Public Offering to Fund Schizophrenia Drug Trial

Reviva Pharma raises $10M via share offering priced at $1.50 per share to fund Phase 3 schizophrenia drug trial through March 2026 closing.
RVPHwarrantspublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Supernus to Present at Three Major Healthcare Conferences in March

Supernus Pharmaceuticals will present at three major healthcare conferences in March 2026, updating investors on strategic initiatives and operational progress.
SUPNinvestor conferencebiopharmaceutical